Stock Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) was the recipient of unusually large options trading on Wednesday. Stock investors purchased 68,587 call options on the stock. This is an increase of 188% compared to the average volume of 23,838 call options.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The combination met the trial’s primary endpoint by significantly extending recurrence-free survival versus Keytruda alone and also reduced the risk of melanoma spreading to distant parts of the body. The results represent the first positive late-stage validation of an mRNA cancer vaccine and could expand Keytruda’s long-term growth opportunity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The announcement generated unusually strong investor interest, with Merck options traders purchasing 68,587 call contracts—about 188% above average daily call volume—suggesting increased bullish positioning. Moderna Rockets, Merck Jumps as Melanoma Therapy Meets Primary Goal
• Neutral Sentiment: Analysts and investors are awaiting complete trial data, including the magnitude and durability of the benefit, safety results, regulatory filings and potential commercialization details. The initial findings are encouraging but do not yet establish the vaccine’s ultimate financial contribution. Melanoma vaccine data boosts outlook, analysts await full results
• Neutral Sentiment: One valuation review characterized Merck at roughly $135.97 as fairly valued, indicating that some of the vaccine optimism may already be reflected in the stock following its move to a new one-year high. Eli Lilly, Novo Nordisk and Merck: Buy, Sell or Hold?

Analysts Set New Price Targets

MRK has been the subject of several research reports. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. BMO Capital Markets lifted their price target on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company upped their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus price target of $135.50.

Merck & Co., Inc. Trading Up 11.6%

NYSE:MRK traded up $15.68 during mid-day trading on Wednesday, hitting $150.85. 21,169,461 shares of the stock traded hands, compared to its average volume of 10,722,418. The stock has a market capitalization of $372.16 billion, a price-to-earnings ratio of 120.51, a PEG ratio of 5.86 and a beta of 0.19. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $151.82. The firm’s 50 day moving average is $126.19 and its two-hundred day moving average is $120.43. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the firm earned $2.13 earnings per share. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities research analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president owned 31,716 shares of the company’s stock, valued at $4,084,069.32. The trade was a 62.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last ninety days. Company insiders own 0.17% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRK. Vanguard Group Inc. increased its stake in shares of Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock valued at $26,770,014,000 after buying an additional 2,185,853 shares during the period. BlackRock Inc. increased its holdings in Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after buying an additional 1,073,507 shares during the period. State Street Corp lifted its stake in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after purchasing an additional 1,859,990 shares during the last quarter. Wellington Management Group LLP boosted its position in Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after purchasing an additional 249,110 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.